Careers  |  Sign In  |  Register  |   Twitter

Biogen’s Hemophilia-A Drug Meets Late-Stage Trial Goals

Biogen Idec Inc said on Wednesday its experimental treatment for patients with hemophilia A, a disorder that inhibits coagulation of the blood, controlled bleeding with fewer treatments in a late-stage clinical trial.

About 30 percent of patients in one arm of the trial were able to go five days without requiring a new dose of the drug, which was, however, a lower percentage than some analysts had expected.”

Read it in Reuters.